Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 82.22M P/E - EPS this Y -6.80% Ern Qtrly Grth -
Income -48.03M Forward P/E -1.35 EPS next Y -112.70% 50D Avg Chg -10.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -44.00%
Recommedations 2.00 Quick Ratio 1.75 Shares Outstanding 62.28M 52W Low Chg 35.00%
Insider Own 30.95% ROA -103.87% Shares Float 43.11M Beta 0.62
Inst Own 15.34% ROE - Shares Shorted/Prior 5.26M/5.01M Price 1.38
Gross Margin - Profit Margin - Avg. Volume 60,974 Target Price -
Oper. Margin - Earnings Date Nov 11 Volume 53,138 Change -1.43%
About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc. News
11/18/24 Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
11/14/24 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
10/15/24 Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
09/30/24 Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
09/03/24 Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/13/24 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
08/01/24 Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
07/30/24 Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%
06/04/24 Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
05/15/24 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
05/13/24 Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
04/09/24 Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
03/29/24 Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
03/29/24 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
03/12/24 Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
06:53 AM Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%
GALT Chatroom

User Image smolcapcat Posted - 41 minutes from now

$GALT give that liver a cup of belapectin

User Image BIGT80 Posted - 1 hour ago

$GALT we be creeping very soon!

User Image D_Coral Posted - 12 hours ago

$GALT Dr. Ben Carson and the new FDA head. This strong relationship with the incoming FDA is good for us. “Dr. Ben Carson sits down with Dr. Marty Makary to discuss the state of the healthcare system and ways to restore public trust.” https://art19.com/shows/common-sense-with-dr-ben-carson/episodes/de716b41-3a58-4c6c-821a-d73aadb98fdf

User Image smolcapcat Posted - 15 hours ago

$GALT lol now we've got people playing this game on both ends

User Image Kilarck Posted - 16 hours ago

$GALT https://www.abc4.com/business/press-releases/globenewswire/9275985/truebinding-receives-fda-ind-go-ahead-for-parkinsons-phase-2a-clinical-trial/ So many uses this company is taking a mAb gal-3 inhibitor into trials to treat Parkinson’s.

User Image Kilarck Posted - 17 hours ago

$GALT This should get a much higher Market cap than Madrigal if effective in showing clinical effect in compensated cirrhosis patients. If this drug actually reduces Gal-3 through the macrophage uptake localized at the site of inflammation so many important implications and uses. Then you have the IO Pd1 story making IO drugs less toxic and more effective is a holy grail. Triple digits share price.

User Image puntthecam Posted - 18 hours ago

$GALT

User Image str8bite Posted - 18 hours ago

$GALT Cmon, announce data release date!

User Image gifor Posted - 21 hours ago

$GALT imho this drug works

User Image smolcapcat Posted - 23 hours ago

$GALT hop in we're headed to December

User Image lucky9150 Posted - 1 day ago

$GALT. , date will be out in mid-December or December end ?

User Image lucky9150 Posted - 1 day ago

$GALT , what will be the price with positive data and data failure??? My guess is $ 15 or 0.50 cents

User Image locallab Posted - 1 day ago

$GALT why so bearish?

User Image BullsOnParade79 Posted - 1 day ago

@Selett @BIGT80 I’m with you but in an earlier post haven’t only a 10% chance of stop for efficacy. I do think the Market is crazy and this $GALT but I think the valuation corrects itself if it moves to P3 with good signs and a clear path. If the market isn’t smart enough to correct the valuation then I bet BP would be.

User Image puntthecam Posted - 1 day ago

$GALT although not an endpoint of the trial, it would be a lifesaver and huge cost savings for many. Thr readout can't come soon enough. I think RFK Jr will have a positive impact on potential Galt acquirers .

User Image gifor Posted - 1 day ago

$GALT a regression of varices in that third of incidental patients would be great absolutely

User Image smolcapcat Posted - 1 day ago

$GALT

User Image BIGT80 Posted - 1 day ago

$GALT I find it odd that anyone would want or even risk shorting this still. A positive outcome based on previous results with this trial state we have a 98% chance of a homer. With only a 2% chance this fails why waste your time and the possibility of losing a shit ton of money? Much easier names to short than this one IMO.

User Image smolcapcat Posted - 1 day ago

$GALT interesting development that might hold Merck's interest in keytruda beyond 2028 https://www.pharmalive.com/merck-says-keytruda-injection-on-par-with-approved-iv-version-in-trial/

User Image BIGT80 Posted - 2 days ago

$GALT I would anticipate less than 30 days to readout.

User Image All_just_a_game Posted - 2 days ago

$GALT So no liver meeting bump….looks like most of the liver drugs are down along with all bio with the RFK news.

User Image smolcapcat Posted - 2 days ago

$GALT follow the data

User Image puntthecam Posted - 2 days ago

$GALT So the trial results show that 2 out of every three patients screened do not show varicies and this is the target population for Belapectin to prevent varicies from occurring. The results of the trial will show how effective Belapectin is in this population. This is huge scientific finding and underscores why the research team is so excited.

User Image BIGT80 Posted - 2 days ago

$GALT still hoping this bumps to $4-5 before readout. Not looking very promising, but stranger things have happened. Was really hoping to take some profit in that range…if not then looks like I push all in until readout…

User Image gifor Posted - 2 days ago

$GALT ALGS has data P2 out tomorrow on the same MASH..

User Image D_Coral Posted - 2 days ago

$GALT

User Image All_just_a_game Posted - 2 days ago

$GALT if it fails in the liver indication is anyone sticking around for the cancer indications? Not sure how to potentially read through a failure in liver fibrosis to the cancer indications.

User Image smolcapcat Posted - 2 days ago

$GALT RFK being forced to eat McDonalds by DJT is bullish for pharma

User Image johnhankowitz Posted - 2 days ago

$GALT Love the PR they put out today. Purely my opinion, but seems like they’re wanting to draw more & more attention to their study/trail and upcoming results. Gut tells me they’re extremely confident & positive results seem likely. I added a few more this morning.

User Image Schuuultz Posted - 3 days ago

$GALT @DanielPT Is this the announcement you may have missed?

Analyst Ratings
HC Wainwright & Co. Buy Aug 16, 24
HC Wainwright & Co. Buy Apr 9, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy May 17, 23
HC Wainwright & Co. Buy Mar 3, 23
HC Wainwright & Co. Buy May 17, 22
HC Wainwright & Co. Buy Apr 16, 21
HC Wainwright & Co. Buy Aug 13, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ELDRED KARY Director Director Jan 16 Buy 1.7858 500 893 49,313 01/16/24
Uihlein Richard E Director Director Sep 26 Option 3.85 2,236,204 8,609,385 10,235,495 09/27/23
ELDRED KARY Director Director Jul 19 Buy 1.786 1,598 2,854 48,813 07/20/23
ELDRED KARY Director Director Feb 21 Buy 1.5911 1,000 1,591 47,215 02/21/23
LEWIS JOEL President and CEO President and CEO Feb 16 Buy 1.52 1,000 1,520 1,000 02/21/23
ELDRED KARY Director Director Jan 25 Buy 1.11 1,300 1,443 46,215 01/26/23
FREEMAN KEVIN D Director Director Oct 28 Buy 1.41 10,000 14,100 75,000 10/31/22
10X Fund, L.P. 10% Owner 10% Owner Jul 27 Sell 2.087 10,000 20,870 6,168,940 08/15/22
10X Fund, L.P. 10% Owner 10% Owner Jul 22 Sell 2.087 10,000 20,870 6,168,940 08/09/22
Zordani Richard A. Jr. Director Director Jul 28 Buy 2.5 5,000 12,500 29,583 07/29/22
FREEMAN KEVIN D Director Director May 19 Buy 1.3299 5,000 6,650 65,000 05/20/22
10X Fund, L.P. 10% Owner 10% Owner Feb 02 Sell 2.10 10,000 21,000 6,178,940 02/04/22
Schwartz Elissa J. Director Director Jan 21 Buy 2 1,000 2,000 1,000 01/24/22
FREEMAN KEVIN D Director Director Jan 19 Buy 1.9612 5,000 9,806 50,000 01/19/22
Zordani Richard A. Jr. Director Director Jan 14 Buy 2.02 5,000 10,100 19,583 01/18/22
10X Fund, L.P. 10% Owner 10% Owner Jan 11 Sell 2.10 10,000 21,000 6,188,940 01/13/22